Frequency of intensive statin therapy in patients with acute coronary syndrome admitted to a tertiary care center

American Journal of Cardiology

Volumn 109, Issue 1, 2012, Pages 1-5

  Shiu, Jennifer R ^a   Pearson, Glen J ^b   Charrois, Theresa L ^c   Gyenes, Gabor ^b   Koshman, Sheri L ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR SURGERY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; INTENSIVE CARE; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT SELECTION; PRIORITY JOURNAL; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CORONARY CARE UNITS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT ADMISSION; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 83555163856     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.07.064     Document Type: Article

References (18)

1. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, D. Waters, A. Zeiher, B.R. Chaitman, S. Leslie, T. Stern Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes JAMA 285 2001 1711 1718
2. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
3. J.A. De Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A. Fox, H.D. White, J.L. Rouleau, T.R. Pedersen, L.H. Gardner, R. Mukherjee, K.E. Ramsey, J. Palmisano, D.W. Bilheimer, M.A. Pfeffer, R.M. Califf, E. Braunwald A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes JAMA 292 2004 1307 1316 (Pubitemid 39223221)
4. K. Josan, S.R. Majumdar, F.A. McAlister The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials Can Med Assoc J 178 2008 576 584 (Pubitemid 351414005)
5. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445 (Pubitemid 44109954)
6. J. Afilalo, A.A. Majdan, M.J. Eisenberg Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials Heart 93 2007 914 921 (Pubitemid 47122038)
7. M. Silva, M.L. Matthews, C. Jarvis, N.M. Nolan, P. Belliveau, M. Malloy, P. Gandhi Meta-analysis of druginduced adverse events associated with intensivedose statin therapy Clin Ther 29 2007 253 260 (Pubitemid 46661859)
8. S.D. Wiviott, C.P. Cannon The safety and efficacy of achieving very low LDLcholesterol concentrations with high dose statin therapy Curr Opin Lipidol 17 2006 626 630 (Pubitemid 44729954)
9. T.A. Jacobson The safety of aggressive statin therapy: how much can low density lipoprotein cholesterol be lowered? Mayo Clin Proc 81 2006 1225 1231 (Pubitemid 44316288)
10. B.A. Steinberg, A.J.M. Braganza, G. Eminowicz, P.M. Dibattiste, G.C. Flaker, S.A. Murphy, C.P. Cannon Are statins being underdosed in clinical practice? Crit Pathw Cardiol 4 2005 169 173
11. F.A. Spencer, R.J. Goldberg, J.M. Gore, K.A. Fox, A. Avezum, G. Agnelli, L. Kritharides, F.A. Anderson, S.G. Goodman, G. FitzGerald, J. Allegrone, D. Brieger GRACE Investigators Comparison of utilization of statin therapy at hospital discharge and sixmonth outcomes in patients with an acute coronary syndrome and serum lowdensity lipoprotein >100 mg/dl versus < 100 mg/dl Am J Cardiol 100 2007 913 918 (Pubitemid 47376671)
12. H.Y. Lee, C.E. Cooke, T.A. Robertson Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge J Manag Care Pharm 14 2008 271 280 (Pubitemid 351711978)
13. N.S. Vermeer, B.V. Bajorek Utilization of evidencebased therapy for the secondary prevention of acute coronary syndromes in Australian practice J Clin Pharm Ther 33 2008 591 601
14. E. Bruckert, G. Hayem, S. Dejager, C. Yau, B. Bégaud Mild to moderate muscular symptoms with highdosage statin therapy in hyperlipidemic patientsthe PRIMO study Cardiovasc Drugs Ther 19 2005 403 414 (Pubitemid 43228152)
15. A.G. Olsson, G.G. Schwartz, M. Szarek, D. Luo, M.J. Jamieson Effects of high-dose atorvastatin in patients >65 years of age with acute coronary syndrome (from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering [MIRACL] study) Am J Cardiol 99 2007 632 635
16. J. Genest, R. McPherson, J. Frohlich, T. Anderson, N. Campbell, A. Carpentier, P. Couture, R. Dufour, G. Fodor, G. Francis, S. Grover, M. Gupta, R.A. Hegele, D.C. Lau, L. Leiter, G.F. Lewis, E. Lonn, G.J. Mancini, D. Ng, G.J. Pearson, A. Sniderman, J.A. Stone, E. Ur Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult2009 recommendations Can J Cardiol 2009 2009 567 579
17. FDA Drug Safety Communication: new restrictions, contradictions, and dose limitations for Zocor (simvastin) to reduce the risk of muscle injury http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm Accessed July 25, 2011
18. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy JAMA 305 2011 2556 2564